Requirements of EU pharmacovigilance

legislation for distributors

Julia SiposQuality Management Director

Pharmacovigilance coordinator

Version 03

Pharmacovigilance

Science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem

(Guideline on good pharmacovigilance practices –GVP - Annex I – Definitions)

2Version 01

Objectives Today’s work supports tomorrow’s safety Pharmacovigilance activities provide

– more information on the pharmaceuticals as• during clinical investigations limited information can be

gained• some impacts may become known in long term only• real environment of use may be different from that of the

clinical investigation– free flow of and access to information on pharmaceutical safety– room for necessary measures to be taken by MAH– useful information to required risk assessment

3Version 01

Tools and scope Tools to achieve the objectives

– continuous collection all available information – share the information gained: report adverse events to the EU

database (according to law)

Scope – Distributed pharmaceuticals where Institute of Isotopes is the

MAH(however other MAHs can have similar requirements)

4Version 01

Definitions

SignalScience and activities relating to the detection, assessment,

understanding and prevention of adverse effects or any other medicine-related problem

Adverse event (AE)Any untoward medical occurrence in a patient or clinical trial subject

administered a medicinal product and which does not necessarily have a causal relationship with this treatment

5Version 01

Definitions

Adverse (drug) reaction (ADR)A response to a medicinal product which is noxious and unintended

Response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility

Adverse reactions may arise from use of the product within or outside the terms of the marketing authorisation or from occupational exposure. Conditions of use outside the marketing authorisation include off-label use, overdose, misuse, abuse and medication errors.

6Version 01

Definitions

Serious adverse event (SAE)An adverse reaction which results in death, is life-threatening, requires

in-patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect.

Life-threatening in this context refers to a reaction in which the patient was at risk of death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if more severe.

7Version 01

Abbreviations

MAH: Marketing Authorization Holder – in this case: Institute of Isotopes

QPPV: Qualified person for pharmacovigilance SDEA: Safety Data Exchange Agreement CIOMS (form): Council for International Organizations of

Medical Sciences - form for Suspect adverse event report

8Version 01

Types of adverse events

Diagram shows the relationships of adverse events, serious adverse events that can be unexpected and drug related

Yellow part shows cases to be reported to the EU database

9Version 01

The legal framework of pharmacovigilance for medicines marketed within the EU/1.

Basic– Regulation (EC) No 726/2004 with respect to centrally authorised

medicinal products

(laying down own Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency)

– Directive 2001/83/EC with respect to nationally authorised medicinal products (including those authorised through the mutual recognition and decentralised systems)

(on the Community code relating to medicinal products for human use)

10Version 01

The legal framework of pharmacovigilance for medicines marketed within the EU/2.

Additional– Commission Implementing Regulation (EU) No

520/2012 includes details in relation to certain aspects of pharmacovigilance to be respected by marketing authorisation holders, national competent authorities and EMA

(on the performance of pharmacovigilance activities provided for in Regulation (EC) No 726/2004 of the European Parliament and of the Council and Directive 2001/83/EC of the European Parliament and of the Council)

– Good pharmacovigilance practice guidelines(GVP) released by EMA in order to facilitate the performance of pharmacovigilance activities. (These GVP modules replace Volume 9A)

11Version 01

The legal framework of pharmacovigilance for medicines marketed in 3rd country.

-2001/83 The MAH shall strive to collect any safety information from 3rd countires (out of EU Community Territory and inform the relevant Agencies, stakeholders accordingly.

Legal background:

EC. (Art 104, paragraph 1 and 4)

- (EC) No 726/2004 – Good pharmacovigilance practice guidelines(GVP) released by EMA in

order to facilitate the performance of pharmacovigilance activities. (These GVP modules replace Volume 9A)

– If regional or local regulations conflict with international guidelines, the stakeholders should follow a conservative approach (i.e., the aim is to be able to comply with the strictest regulation).

12Version 01

Requirements for distributors/1. To be familiar with relevant requirements of EU legislation

on pharmacovigilance To be familiar with their national legislation on

pharmacovigilance Share with MAHs the following information as a minimum:

– national requirements for pharmacovigilance– access data of person responsible for receiving all incoming

information on drug safety (adverse reactions): name, e-mail, phone number, address.

Any changes in these data shall be reported immediately to the MAH’s QPPV.

13Version 01

Requirements for distributors/2

Conclude a SDEA with the MAHs – covering in detail all co-operation– activities– tasks and– responsibilities

of the parties in terms of pharmacovigilanceContinuous screening of domestic professional literature

for any safety issues of the distributed pharmaceuticals – report any signals to MAHs

14Version 01

Requirements for distributors/3

Encourage their partners (health institutions and/or health care professionals and/or patients as applicable) to report all information on drug safety

For this purpose:– share contact data with their partners– provide information on the 4 necessary (minimum) data to

MAH – see next slide

– forward all information arriving from the MAH to their partners in this issue in due time

– inform their partners on further fate of their reported signals or adverse/pregnancy events

15Version 01

Requirements for distributors/4

Information may arrive from– patients/their relatives or– healthcare professionals

Collect and provide all follow-up information if required by MAH– additional data related to the reported case– answer on authorities’ requests

Meet time frames required by MAH for Pharmacovigilance information must not be made public

16Version 01

Reporting to MAH Report

– signals, adverse or pregnancy event information to the MAH’s QPPV– immediately– via e-mail or fax using free text or phone or using CIOMS form

(Can be downloaded from: http://www.cioms.ch/)

At least four basic data shall be included– data of the reporter (name, address, access data, e.g. e-mail address

or phone number)– patient data (monogram or identification code, date of birth or age,

sex)– at least one suspected pharmaceutical– at least one suspected adverse event

17Version 01

Special casesInstitute of Isotopes (IoI) is distributor of a product of another

MAH

In case of incoming event report– the same information should be sent to that MAH as in case of

IoI’s product and– please send to IoI as well for information– if no contact is available to the MAH, send the information to IoI

18Version 01

Contacts at IoI

Pharmacovigilance Coordinator (connection to QPPV)Sipos, Julia

e-mail: gyogyszerbiztonsag@izotop.hu

phone: +36-1- 391-0900

mobile: +36-30-991-0468 (available 24 hours/day)

19Version 01

20

Contact us in case of any questions!

THANK YOU FOR YOUR ATTENTION!

Version 01